— Acasti Pharma Inc. (NASDAQ: ACST) reported Q3 2020 net loss of CAD15.7 million, or CAD0.18 per share, compared to net loss of CAD4.6 million, or CAD0.07 per share, last year.
— Loss from operating activities was CAD7.9 million compared to a loss of CAD10.7 million last year.
— R&D expenses before depreciation, amortization and stock-based compensation expenses were CAD4.2 million compared to CAD8.8 million last year.
— General and administrative expenses before stock-based compensation expenses were CAD1.6 million versus CAD0.76 million last year.
— Sales and marketing expenses before stock-based compensation expenses were CAD0.74 million compared to CAD0.13 million last year.
— Cash and cash equivalents and marketable securities totaled CAD25.7 million as of December 31, 2019.
— ACST shares gained 0.69% immediately following the announcement.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
Key highlights from Bank of America’s (BAC) Q4 2024 earnings results
Bank of America Corporation (NYSE: BAC) reported its fourth quarter 2024 earnings results today. Revenue, net of interest expense, was $25.3 billion, up 15% year-over-year. Net income was $6.7 billion,
US Bancorp (USB) Q4 profit rises on higher revenues, beats estimates
U.S. Bancorp (NYSE: USB) Thursday reported an increase in revenue and profit for the fourth quarter of 2024. Earnings also came in above analysts' forecasts. Total net revenue increased 3.7%
UnitedHealth Group (UNH) Q4 2024 Earnings: Key financials and quarterly highlights
UnitedHealth Group (NYSE: UNH) reported its fourth quarter 2024 earnings results today. Total revenues were $100.8 billion compared to $94.4 billion reported in the same period a year ago. Net